Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease

Geert D’Haens , Severine Vermeire , Guy Lambrecht , Filip Baert , Peter Bossuyt , Benjamin Pariente , Anthony Buisson , Yoram Bouhnik, Jérôme Filippi , Janneke Vander Woude , Philippe Van Hootegem , Jacques Moreau , Edouard Louis , Denis Franchimont , Martine De Vos , Fazia Mana , Laurent Peyrin-Biroulet , Hedia Brixi , Matthieu Allez , Philip Caenepeel , Alexandre Aubourg , Bas Oldenburg , Marieke Pierik , Ann Gils , Sylvie Chevret , David Laharie

(Gastroenterology . 2018 Apr;154(5):1343-1351.e1 – PMID: 29317275)

https://pubmed.ncbi.nlm.nih.gov/29317275/